Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksByotrol Regulatory News (BYOT)

Share Price Information for Byotrol (BYOT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.10
Bid: 0.05
Ask: 0.15
Change: 0.00 (0.00%)
Spread: 0.10 (200.00%)
Open: 0.125
High: 0.00
Low: 0.00
Prev. Close: 0.10
BYOT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Licence and Product Supply Agreement with Tristel

23 Mar 2020 07:00

RNS Number : 1185H
Byotrol PLC
23 March 2020
 

 

 

 

 

Byotrol plc ("Byotrol" or the "Company")

Know-How Licence and Product Supply Agreement with Tristel plc

 

 

Byotrol is pleased to announce a new collaboration ("the Agreement") with fellow infection prevention and control specialists Tristel plc.

 

The Agreement relates to three specific technologies

 

1. A concentrated surface disinfectant initially targeted for use in hospitals, dispensed from Tristel's proprietary Cache system of innovative packaging solutions; and

2. A concentrated surface disinfectant with long-lasting (8 hour) anti-microbial efficacy also to be dispensed from Tristel's proprietary Cache system. This product is a concentrate version of ACTIZONE, a Solvay technology developed in conjunction with Byotrol; and

3. A unique surface disinfectant combining Tristel's proprietary sporicidal chemistry, with Byotrol's long-lasting anti-microbial technology, also based on the ACTIZONE technology platform. The combined product will speedily eliminate spores on application, and will then remain active against microbes for an 8-hour period after application. Tristel will incorporate the jointly developed formulation in several packaging formats under the family name "Tristel8". 

The Agreement has a duration of 10 years and will be exclusive in hospitals in the UK and Ireland and non-exclusive elsewhere. Under the terms of the Agreement, Tristel will pay to Byotrol a combination of product supply payments, royalties and fees, based on success but with meaningful minimum guarantee payments to Byotrol each year.

 

 

David Traynor, Chief Executive of Byotrol, said:

 

"We are really pleased to be working with Tristel in this way and are particularly pleased that our chemistries now work in combination, with genuinely unique new product claims at a key time in infection control. This agreement now brings our products to many more customers in healthcare and beyond, and in formats that we could not do on our own"

 

 

Enquiries:

 

Byotrol plc

David Traynor - Chief Executive Officer

Nic Hellyer - Chief Financial Officer 01925 742 000

 

finnCap

Geoff Nash/ Richard Chambers - Corporate Finance 020 7220 0500

 

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading infection prevention and control technology company, operating globally in the Food, Industrial, Healthcare and Consumer sectors, providing low toxicity products with a broad-based and long-lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, mycobacteria and algae.

 

Powerful, long-lasting and gentle, Byotrol's products can be used stand-alone or as ingredients within existing products, where Byotrol can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company develops technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to www.byotrol.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRJTMMTMTMTTJM
Date   Source Headline
20th Aug 20151:00 pmRNSPlacing and Subscription to raise £1.4 million
14th Aug 20157:00 amRNSPosting of Annual Report and Notice of AGM
4th Aug 20157:00 amRNSAgreement with Solvay
1st Jul 20158:25 amRNSHolding(s) in Company
15th Jun 20157:00 amRNSPreliminary Results
16th Apr 20157:00 amRNSTrading update
25th Nov 20147:01 amRNSInterim Results
25th Nov 20147:00 amRNSBoard Appointment
10th Nov 201410:58 amRNSNotice of Interim Results
17th Sep 20141:08 pmRNSHolding(s) in Company
29th Jul 20143:35 pmRNSResult of AGM and Completion of Placing
24th Jul 20147:00 amRNSGrant of Options
7th Jul 20147:00 amRNSANNUAL REPORT AND AGM NOTICE
25th Jun 20147:00 amRNSUnaudited Preliminary Results
25th Jun 20147:00 amRNSConditional Fundraising of £1.25m
18th Mar 20147:00 amRNSTrading Update and Directorate Changes
20th Dec 20137:00 amRNSFundraising
19th Nov 20137:00 amRNSInterim Results
31st Oct 20137:00 amRNSTotal Voting Rights
17th Oct 20133:04 pmRNSHolding(s) in Company
10th Oct 20133:11 pmRNSHolding(s) in Company
9th Oct 20137:00 amRNSDirectorate Change
3rd Oct 20137:00 amRNSAcquisition
15th Aug 20138:34 amRNSDirector/PDMR Shareholding
13th Aug 20133:12 pmRNSDirector/PDMR Shareholding
9th Aug 20132:47 pmRNSDirector/PDMR Shareholding
9th Aug 20138:20 amRNSHolding(s) in Company
25th Jul 20133:54 pmRNSResult of AGM
1st Jul 20139:28 amRNSDirector/PDMR Shareholding
25th Jun 20137:01 amRNSIssue of Equity
25th Jun 20137:00 amRNSFinal Results
19th Apr 20137:00 amRNSDirectorate Change
19th Mar 20137:00 amRNSJDA with Albaad Ltd for UK & Europe
8th Feb 20137:00 amRNSCommercial & Trading Update
20th Nov 20127:00 amRNSInterim Results
1st Oct 20129:44 amRNSDirector/PDMR Shareholding
16th Aug 201210:25 amRNSDirector/PDMR Shareholding
14th Aug 20126:08 pmRNSHolding(s) in Company
13th Aug 20127:00 amRNSLicensing Agreement with Kimberly-Clark
25th Jul 20127:00 amRNSHolding(s) in Company
23rd Jul 20128:03 amRNSHolding(s) in Company
19th Jul 20123:33 pmRNSResult of AGM
19th Jul 20127:00 amRNSAGM Statement
17th Jul 201211:10 amRNSDirector/PDMR Shareholding
6th Jul 20127:00 amRNSGrant of Options
27th Jun 20127:00 amRNSDirectorate Change + Annual Report + AGM notice
19th Jun 20127:00 amRNSPreliminary Results
12th Apr 20127:00 amRNSTrading Update
10th Feb 201210:54 amRNSHolding(s) in Company
31st Jan 20122:00 pmRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.